B cells from CLL patients were cultured in medium alone or in the presence of increasing concentrations of AG490, a JAK2 inhibitor, in order to inactivate the JAK2/STAT3 axis and to assess the cell viability after 24, 48, and 72 h of treatment. The gene discussed is JAK2; the disease is B-cell chronic lymphocytic leukemia.